nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CYP1A1—kidney cancer	0.17	0.653	CbGaD
Haloperidol—ABCB1—kidney cancer	0.0903	0.347	CbGaD
Haloperidol—CBR1—Doxorubicin—kidney cancer	0.0657	0.127	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.0297	0.0573	CbGbCtD
Haloperidol—CYP3A7—Temsirolimus—kidney cancer	0.0297	0.0573	CbGbCtD
Haloperidol—UGT1A9—Sorafenib—kidney cancer	0.0273	0.0526	CbGbCtD
Haloperidol—CYP3A5—Temsirolimus—kidney cancer	0.0223	0.043	CbGbCtD
Haloperidol—HTR2B—Sorafenib—kidney cancer	0.0214	0.0412	CbGbCtD
Haloperidol—ABCB1—Temsirolimus—kidney cancer	0.0145	0.028	CbGbCtD
Haloperidol—KCNH2—Sunitinib—kidney cancer	0.0144	0.0277	CbGbCtD
Haloperidol—CYP1A1—Erlotinib—kidney cancer	0.0139	0.0269	CbGbCtD
Haloperidol—CYP2D6—Temsirolimus—kidney cancer	0.0137	0.0264	CbGbCtD
Haloperidol—CYP3A4—Everolimus—kidney cancer	0.0129	0.0248	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.0102	0.0197	CbGbCtD
Haloperidol—CYP3A7—Paclitaxel—kidney cancer	0.0102	0.0197	CbGbCtD
Haloperidol—CYP3A7—Sorafenib—kidney cancer	0.00906	0.0175	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.00906	0.0175	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.0088	0.017	CbGbCtD
Haloperidol—CYP3A7—Vincristine—kidney cancer	0.0088	0.017	CbGbCtD
Haloperidol—CYP1A2—Pazopanib—kidney cancer	0.00872	0.0168	CbGbCtD
Haloperidol—CYP3A4—Temsirolimus—kidney cancer	0.0087	0.0168	CbGbCtD
Haloperidol—CYP3A5—Erlotinib—kidney cancer	0.00836	0.0161	CbGbCtD
Haloperidol—CYP2C9—Capecitabine—kidney cancer	0.0082	0.0158	CbGbCtD
Haloperidol—CYP3A5—Paclitaxel—kidney cancer	0.00765	0.0148	CbGbCtD
Haloperidol—ABCB1—Pazopanib—kidney cancer	0.00763	0.0147	CbGbCtD
Haloperidol—CYP3A7—Sunitinib—kidney cancer	0.00734	0.0142	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.00734	0.0142	CbGbCtD
Haloperidol—CYP2D6—Pazopanib—kidney cancer	0.00719	0.0139	CbGbCtD
Haloperidol—ABCB1—Dactinomycin—kidney cancer	0.00698	0.0134	CbGbCtD
Haloperidol—CYP3A5—Sorafenib—kidney cancer	0.0068	0.0131	CbGbCtD
Haloperidol—CYP3A5—Vincristine—kidney cancer	0.0066	0.0127	CbGbCtD
Haloperidol—CYP1A2—Erlotinib—kidney cancer	0.00622	0.012	CbGbCtD
Haloperidol—ABCB1—Gemcitabine—kidney cancer	0.00551	0.0106	CbGbCtD
Haloperidol—CYP3A5—Sunitinib—kidney cancer	0.00551	0.0106	CbGbCtD
Haloperidol—CYP2C19—Sorafenib—kidney cancer	0.00548	0.0106	CbGbCtD
Haloperidol—ABCB1—Erlotinib—kidney cancer	0.00544	0.0105	CbGbCtD
Haloperidol—CYP2C9—Paclitaxel—kidney cancer	0.00513	0.0099	CbGbCtD
Haloperidol—CYP2D6—Erlotinib—kidney cancer	0.00513	0.00989	CbGbCtD
Haloperidol—CYP1A2—Sorafenib—kidney cancer	0.00506	0.00976	CbGbCtD
Haloperidol—ABCB1—Paclitaxel—kidney cancer	0.00498	0.00961	CbGbCtD
Haloperidol—CYP3A4—Pazopanib—kidney cancer	0.00457	0.00881	CbGbCtD
Haloperidol—CYP2C9—Sorafenib—kidney cancer	0.00456	0.00879	CbGbCtD
Haloperidol—ABCB1—Sorafenib—kidney cancer	0.00443	0.00853	CbGbCtD
Haloperidol—ABCB1—Vinblastine—kidney cancer	0.00437	0.00842	CbGbCtD
Haloperidol—ABCB1—Vincristine—kidney cancer	0.0043	0.00828	CbGbCtD
Haloperidol—CYP2D6—Sorafenib—kidney cancer	0.00417	0.00804	CbGbCtD
Haloperidol—CYP2D6—Vinblastine—kidney cancer	0.00412	0.00794	CbGbCtD
Haloperidol—ABCB1—Sunitinib—kidney cancer	0.00359	0.00691	CbGbCtD
Haloperidol—CYP3A4—Erlotinib—kidney cancer	0.00326	0.00629	CbGbCtD
Haloperidol—CYP3A4—Paclitaxel—kidney cancer	0.00298	0.00575	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—kidney cancer	0.00268	0.00518	CbGbCtD
Haloperidol—CYP3A4—Sorafenib—kidney cancer	0.00265	0.00511	CbGbCtD
Haloperidol—CYP3A4—Vinblastine—kidney cancer	0.00262	0.00505	CbGbCtD
Haloperidol—CYP3A4—Vincristine—kidney cancer	0.00257	0.00496	CbGbCtD
Haloperidol—CYP2D6—Doxorubicin—kidney cancer	0.00253	0.00488	CbGbCtD
Haloperidol—CYP3A4—Sunitinib—kidney cancer	0.00215	0.00414	CbGbCtD
Haloperidol—CYP2C19—urine—kidney cancer	0.00186	0.0595	CbGeAlD
Haloperidol—CYP3A4—Doxorubicin—kidney cancer	0.00161	0.0031	CbGbCtD
Haloperidol—CYP1A2—urine—kidney cancer	0.00152	0.0486	CbGeAlD
Haloperidol—CYP2C9—urine—kidney cancer	0.00144	0.0461	CbGeAlD
Haloperidol—UGT1A9—renal system—kidney cancer	0.00123	0.0392	CbGeAlD
Haloperidol—HTR2A—urine—kidney cancer	0.00119	0.038	CbGeAlD
Haloperidol—UGT1A9—kidney—kidney cancer	0.00118	0.0379	CbGeAlD
Haloperidol—CYP3A4—urine—kidney cancer	0.0011	0.0352	CbGeAlD
Haloperidol—CYP2D6—urine—kidney cancer	0.00108	0.0346	CbGeAlD
Haloperidol—CBR1—nephron tubule—kidney cancer	0.00101	0.0324	CbGeAlD
Haloperidol—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.000953	0.0305	CbGeAlD
Haloperidol—CBR1—renal system—kidney cancer	0.000922	0.0295	CbGeAlD
Haloperidol—CBR1—kidney—kidney cancer	0.000891	0.0285	CbGeAlD
Haloperidol—CBR1—cortex of kidney—kidney cancer	0.000868	0.0278	CbGeAlD
Haloperidol—H1F0—nephron tubule—kidney cancer	0.000831	0.0266	CbGeAlD
Haloperidol—CBR1—gonad—kidney cancer	0.000827	0.0264	CbGeAlD
Haloperidol—CBR1—cardiac atrium—kidney cancer	0.000826	0.0264	CbGeAlD
Haloperidol—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.000816	0.0261	CbGeAlD
Haloperidol—H1F0—renal system—kidney cancer	0.000755	0.0241	CbGeAlD
Haloperidol—H1F0—kidney—kidney cancer	0.00073	0.0233	CbGeAlD
Haloperidol—H1F0—cortex of kidney—kidney cancer	0.000711	0.0227	CbGeAlD
Haloperidol—Loperamide—POMC—kidney cancer	0.000707	0.894	CrCbGaD
Haloperidol—EBP—Sirolimus—Everolimus—kidney cancer	0.000678	0.222	CbGdCrCtD
Haloperidol—EBP—Temsirolimus—Everolimus—kidney cancer	0.000678	0.222	CbGdCrCtD
Haloperidol—EBP—Sirolimus—Temsirolimus—kidney cancer	0.000678	0.222	CbGdCrCtD
Haloperidol—H1F0—gonad—kidney cancer	0.000677	0.0217	CbGeAlD
Haloperidol—H1F0—cardiac atrium—kidney cancer	0.000677	0.0216	CbGeAlD
Haloperidol—SIGMAR1—nephron tubule—kidney cancer	0.0006	0.0192	CbGeAlD
Haloperidol—CBR1—Vincristine—Vinblastine—kidney cancer	0.000569	0.186	CbGdCrCtD
Haloperidol—HTR1D—kidney—kidney cancer	0.000566	0.0181	CbGeAlD
Haloperidol—SIGMAR1—cortex of kidney—kidney cancer	0.000514	0.0164	CbGeAlD
Haloperidol—HTR2B—cortex of kidney—kidney cancer	0.000513	0.0164	CbGeAlD
Haloperidol—SIGMAR1—cardiac atrium—kidney cancer	0.000489	0.0156	CbGeAlD
Haloperidol—KCNH2—renal system—kidney cancer	0.000434	0.0139	CbGeAlD
Haloperidol—CYP3A5—nephron tubule—kidney cancer	0.000394	0.0126	CbGeAlD
Haloperidol—KCNH2—cardiac atrium—kidney cancer	0.000389	0.0124	CbGeAlD
Haloperidol—CYP1A2—renal system—kidney cancer	0.000372	0.0119	CbGeAlD
Haloperidol—CYP1A1—renal system—kidney cancer	0.000367	0.0117	CbGeAlD
Haloperidol—CYP3A5—renal system—kidney cancer	0.000359	0.0115	CbGeAlD
Haloperidol—CYP1A1—kidney—kidney cancer	0.000355	0.0113	CbGeAlD
Haloperidol—CYP3A5—kidney—kidney cancer	0.000347	0.0111	CbGeAlD
Haloperidol—CYP3A5—cortex of kidney—kidney cancer	0.000338	0.0108	CbGeAlD
Haloperidol—CYP1A1—cardiac atrium—kidney cancer	0.000328	0.0105	CbGeAlD
Haloperidol—HTR2A—renal system—kidney cancer	0.000291	0.00929	CbGeAlD
Haloperidol—HTR2A—kidney—kidney cancer	0.000281	0.00898	CbGeAlD
Haloperidol—CYP3A4—renal system—kidney cancer	0.000269	0.0086	CbGeAlD
Haloperidol—CBR1—Azacitidine—Gemcitabine—kidney cancer	0.000268	0.0878	CbGdCrCtD
Haloperidol—CYP2D6—renal system—kidney cancer	0.000265	0.00847	CbGeAlD
Haloperidol—HTR2A—gonad—kidney cancer	0.000261	0.00833	CbGeAlD
Haloperidol—CYP3A4—kidney—kidney cancer	0.00026	0.00832	CbGeAlD
Haloperidol—CYP2D6—kidney—kidney cancer	0.000256	0.00818	CbGeAlD
Haloperidol—ABCB1—nephron tubule—kidney cancer	0.00021	0.0067	CbGeAlD
Haloperidol—ABCB1—renal system—kidney cancer	0.00019	0.00609	CbGeAlD
Haloperidol—ABCB1—kidney—kidney cancer	0.000184	0.00589	CbGeAlD
Haloperidol—EBP—Azacitidine—Gemcitabine—kidney cancer	0.000182	0.0597	CbGdCrCtD
Haloperidol—ABCB1—cortex of kidney—kidney cancer	0.000179	0.00573	CbGeAlD
Haloperidol—ABCB1—gonad—kidney cancer	0.000171	0.00546	CbGeAlD
Haloperidol—Diarrhoea—Everolimus—kidney cancer	0.000117	0.000904	CcSEcCtD
Haloperidol—Hyperhidrosis—Vincristine—kidney cancer	0.000117	0.000902	CcSEcCtD
Haloperidol—Hepatobiliary disease—Capecitabine—kidney cancer	0.000117	0.000902	CcSEcCtD
Haloperidol—Pruritus—Erlotinib—kidney cancer	0.000116	0.000902	CcSEcCtD
Haloperidol—Agranulocytosis—Capecitabine—kidney cancer	0.000115	0.00089	CcSEcCtD
Haloperidol—Anorexia—Vincristine—kidney cancer	0.000115	0.00089	CcSEcCtD
Haloperidol—Oedema—Gemcitabine—kidney cancer	0.000114	0.000885	CcSEcCtD
Haloperidol—Anaphylactic shock—Gemcitabine—kidney cancer	0.000114	0.000885	CcSEcCtD
Haloperidol—Dizziness—Vinblastine—kidney cancer	0.000113	0.000877	CcSEcCtD
Haloperidol—Dizziness—Everolimus—kidney cancer	0.000113	0.000873	CcSEcCtD
Haloperidol—Muscle spasms—Paclitaxel—kidney cancer	0.000113	0.000873	CcSEcCtD
Haloperidol—Body temperature increased—Sunitinib—kidney cancer	0.000113	0.000872	CcSEcCtD
Haloperidol—Diarrhoea—Erlotinib—kidney cancer	0.000113	0.000872	CcSEcCtD
Haloperidol—Hypotension—Vincristine—kidney cancer	0.000113	0.000872	CcSEcCtD
Haloperidol—Nervous system disorder—Gemcitabine—kidney cancer	0.000112	0.000868	CcSEcCtD
Haloperidol—Thrombocytopenia—Gemcitabine—kidney cancer	0.000112	0.000867	CcSEcCtD
Haloperidol—Feeling abnormal—Dactinomycin—kidney cancer	0.000111	0.000861	CcSEcCtD
Haloperidol—Skin disorder—Gemcitabine—kidney cancer	0.000111	0.00086	CcSEcCtD
Haloperidol—Hepatitis—Capecitabine—kidney cancer	0.000111	0.000856	CcSEcCtD
Haloperidol—Vision blurred—Paclitaxel—kidney cancer	0.000111	0.000856	CcSEcCtD
Haloperidol—Hyperhidrosis—Gemcitabine—kidney cancer	0.000111	0.000856	CcSEcCtD
Haloperidol—Tremor—Paclitaxel—kidney cancer	0.00011	0.000851	CcSEcCtD
Haloperidol—Urinary tract disorder—Capecitabine—kidney cancer	0.000109	0.000845	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Doxorubicin—kidney cancer	0.000109	0.000845	CcSEcCtD
Haloperidol—Hypersensitivity—Sorafenib—kidney cancer	0.000109	0.000845	CcSEcCtD
Haloperidol—Insomnia—Vincristine—kidney cancer	0.000109	0.000844	CcSEcCtD
Haloperidol—Anorexia—Gemcitabine—kidney cancer	0.000109	0.000844	CcSEcCtD
Haloperidol—Vomiting—Vinblastine—kidney cancer	0.000109	0.000843	CcSEcCtD
Haloperidol—Dizziness—Erlotinib—kidney cancer	0.000109	0.000843	CcSEcCtD
Haloperidol—Connective tissue disorder—Capecitabine—kidney cancer	0.000109	0.000841	CcSEcCtD
Haloperidol—Vomiting—Everolimus—kidney cancer	0.000108	0.00084	CcSEcCtD
Haloperidol—Anaemia—Paclitaxel—kidney cancer	0.000108	0.000839	CcSEcCtD
Haloperidol—Urethral disorder—Capecitabine—kidney cancer	0.000108	0.000839	CcSEcCtD
Haloperidol—Agitation—Paclitaxel—kidney cancer	0.000108	0.000835	CcSEcCtD
Haloperidol—Rash—Everolimus—kidney cancer	0.000108	0.000833	CcSEcCtD
Haloperidol—Dermatitis—Everolimus—kidney cancer	0.000107	0.000832	CcSEcCtD
Haloperidol—Headache—Vinblastine—kidney cancer	0.000107	0.000831	CcSEcCtD
Haloperidol—Headache—Everolimus—kidney cancer	0.000107	0.000828	CcSEcCtD
Haloperidol—Hypotension—Gemcitabine—kidney cancer	0.000107	0.000827	CcSEcCtD
Haloperidol—Body temperature increased—Dactinomycin—kidney cancer	0.000107	0.000826	CcSEcCtD
Haloperidol—Visual impairment—Capecitabine—kidney cancer	0.000107	0.000825	CcSEcCtD
Haloperidol—Hypoglycaemia—Doxorubicin—kidney cancer	0.000106	0.000817	CcSEcCtD
Haloperidol—Vertigo—Paclitaxel—kidney cancer	0.000105	0.000816	CcSEcCtD
Haloperidol—Lethargy—Doxorubicin—kidney cancer	0.000105	0.000814	CcSEcCtD
Haloperidol—Leukopenia—Paclitaxel—kidney cancer	0.000105	0.000813	CcSEcCtD
Haloperidol—Hypersensitivity—Sunitinib—kidney cancer	0.000105	0.000813	CcSEcCtD
Haloperidol—Decreased appetite—Vincristine—kidney cancer	0.000105	0.000811	CcSEcCtD
Haloperidol—Pruritus—Sorafenib—kidney cancer	0.000105	0.000811	CcSEcCtD
Haloperidol—Vomiting—Erlotinib—kidney cancer	0.000105	0.00081	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Vincristine—kidney cancer	0.000104	0.000806	CcSEcCtD
Haloperidol—Rash—Erlotinib—kidney cancer	0.000104	0.000804	CcSEcCtD
Haloperidol—Dermatitis—Erlotinib—kidney cancer	0.000104	0.000803	CcSEcCtD
Haloperidol—Hyponatraemia—Doxorubicin—kidney cancer	0.000103	0.000801	CcSEcCtD
Haloperidol—Insomnia—Gemcitabine—kidney cancer	0.000103	0.000801	CcSEcCtD
Haloperidol—Eye disorder—Capecitabine—kidney cancer	0.000103	0.0008	CcSEcCtD
Haloperidol—Headache—Erlotinib—kidney cancer	0.000103	0.000798	CcSEcCtD
Haloperidol—Constipation—Vincristine—kidney cancer	0.000103	0.000798	CcSEcCtD
Haloperidol—Cardiac disorder—Capecitabine—kidney cancer	0.000103	0.000795	CcSEcCtD
Haloperidol—Dyspnoea—Gemcitabine—kidney cancer	0.000102	0.000789	CcSEcCtD
Haloperidol—Nausea—Vinblastine—kidney cancer	0.000102	0.000788	CcSEcCtD
Haloperidol—Somnolence—Gemcitabine—kidney cancer	0.000102	0.000787	CcSEcCtD
Haloperidol—Convulsion—Paclitaxel—kidney cancer	0.000102	0.000787	CcSEcCtD
Haloperidol—Nausea—Everolimus—kidney cancer	0.000101	0.000785	CcSEcCtD
Haloperidol—Diarrhoea—Sorafenib—kidney cancer	0.000101	0.000785	CcSEcCtD
Haloperidol—Hypertension—Paclitaxel—kidney cancer	0.000101	0.000784	CcSEcCtD
Haloperidol—Pruritus—Sunitinib—kidney cancer	0.000101	0.000781	CcSEcCtD
Haloperidol—Angiopathy—Capecitabine—kidney cancer	0.0001	0.000777	CcSEcCtD
Haloperidol—Immune system disorder—Capecitabine—kidney cancer	9.99e-05	0.000773	CcSEcCtD
Haloperidol—Mediastinal disorder—Capecitabine—kidney cancer	9.97e-05	0.000772	CcSEcCtD
Haloperidol—Anxiety—Paclitaxel—kidney cancer	9.95e-05	0.000771	CcSEcCtD
Haloperidol—Face oedema—Doxorubicin—kidney cancer	9.95e-05	0.00077	CcSEcCtD
Haloperidol—Decreased appetite—Gemcitabine—kidney cancer	9.94e-05	0.00077	CcSEcCtD
Haloperidol—Hypersensitivity—Dactinomycin—kidney cancer	9.94e-05	0.00077	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	9.92e-05	0.000768	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Gemcitabine—kidney cancer	9.87e-05	0.000764	CcSEcCtD
Haloperidol—Cardiac arrest—Doxorubicin—kidney cancer	9.8e-05	0.000759	CcSEcCtD
Haloperidol—Dizziness—Sorafenib—kidney cancer	9.79e-05	0.000758	CcSEcCtD
Haloperidol—Constipation—Gemcitabine—kidney cancer	9.78e-05	0.000757	CcSEcCtD
Haloperidol—Nausea—Erlotinib—kidney cancer	9.78e-05	0.000757	CcSEcCtD
Haloperidol—Alopecia—Capecitabine—kidney cancer	9.77e-05	0.000757	CcSEcCtD
Haloperidol—Dry mouth—Paclitaxel—kidney cancer	9.77e-05	0.000756	CcSEcCtD
Haloperidol—Diarrhoea—Sunitinib—kidney cancer	9.75e-05	0.000755	CcSEcCtD
Haloperidol—Mental disorder—Capecitabine—kidney cancer	9.69e-05	0.00075	CcSEcCtD
Haloperidol—Confusional state—Paclitaxel—kidney cancer	9.65e-05	0.000747	CcSEcCtD
Haloperidol—Malnutrition—Capecitabine—kidney cancer	9.63e-05	0.000745	CcSEcCtD
Haloperidol—Anaphylactic shock—Paclitaxel—kidney cancer	9.57e-05	0.000741	CcSEcCtD
Haloperidol—Oedema—Paclitaxel—kidney cancer	9.57e-05	0.000741	CcSEcCtD
Haloperidol—Body temperature increased—Vincristine—kidney cancer	9.53e-05	0.000738	CcSEcCtD
Haloperidol—Liver function test abnormal—Doxorubicin—kidney cancer	9.51e-05	0.000737	CcSEcCtD
Haloperidol—Dizziness—Sunitinib—kidney cancer	9.42e-05	0.00073	CcSEcCtD
Haloperidol—Feeling abnormal—Gemcitabine—kidney cancer	9.42e-05	0.00073	CcSEcCtD
Haloperidol—Vomiting—Sorafenib—kidney cancer	9.42e-05	0.000729	CcSEcCtD
Haloperidol—Orthostatic hypotension—Doxorubicin—kidney cancer	9.41e-05	0.000729	CcSEcCtD
Haloperidol—Nervous system disorder—Paclitaxel—kidney cancer	9.39e-05	0.000727	CcSEcCtD
Haloperidol—Thrombocytopenia—Paclitaxel—kidney cancer	9.37e-05	0.000726	CcSEcCtD
Haloperidol—Tachycardia—Paclitaxel—kidney cancer	9.34e-05	0.000723	CcSEcCtD
Haloperidol—Rash—Sorafenib—kidney cancer	9.34e-05	0.000723	CcSEcCtD
Haloperidol—Dermatitis—Sorafenib—kidney cancer	9.33e-05	0.000722	CcSEcCtD
Haloperidol—Breast disorder—Doxorubicin—kidney cancer	9.31e-05	0.000721	CcSEcCtD
Haloperidol—Skin disorder—Paclitaxel—kidney cancer	9.3e-05	0.00072	CcSEcCtD
Haloperidol—Headache—Sorafenib—kidney cancer	9.28e-05	0.000718	CcSEcCtD
Haloperidol—Muscle spasms—Capecitabine—kidney cancer	9.26e-05	0.000717	CcSEcCtD
Haloperidol—Hyperhidrosis—Paclitaxel—kidney cancer	9.26e-05	0.000717	CcSEcCtD
Haloperidol—Diarrhoea—Dactinomycin—kidney cancer	9.23e-05	0.000715	CcSEcCtD
Haloperidol—Anorexia—Paclitaxel—kidney cancer	9.13e-05	0.000707	CcSEcCtD
Haloperidol—Vision blurred—Capecitabine—kidney cancer	9.07e-05	0.000702	CcSEcCtD
Haloperidol—Vomiting—Sunitinib—kidney cancer	9.06e-05	0.000701	CcSEcCtD
Haloperidol—Body temperature increased—Gemcitabine—kidney cancer	9.04e-05	0.0007	CcSEcCtD
Haloperidol—Tremor—Capecitabine—kidney cancer	9.02e-05	0.000698	CcSEcCtD
Haloperidol—Rash—Sunitinib—kidney cancer	8.99e-05	0.000696	CcSEcCtD
Haloperidol—Dermatitis—Sunitinib—kidney cancer	8.98e-05	0.000695	CcSEcCtD
Haloperidol—Hypotension—Paclitaxel—kidney cancer	8.95e-05	0.000693	CcSEcCtD
Haloperidol—Headache—Sunitinib—kidney cancer	8.93e-05	0.000691	CcSEcCtD
Haloperidol—Dysphagia—Doxorubicin—kidney cancer	8.91e-05	0.000689	CcSEcCtD
Haloperidol—Anaemia—Capecitabine—kidney cancer	8.9e-05	0.000689	CcSEcCtD
Haloperidol—Hypersensitivity—Vincristine—kidney cancer	8.88e-05	0.000688	CcSEcCtD
Haloperidol—Nausea—Sorafenib—kidney cancer	8.8e-05	0.000681	CcSEcCtD
Haloperidol—Insomnia—Paclitaxel—kidney cancer	8.66e-05	0.00067	CcSEcCtD
Haloperidol—Vertigo—Capecitabine—kidney cancer	8.65e-05	0.00067	CcSEcCtD
Haloperidol—Leukopenia—Capecitabine—kidney cancer	8.62e-05	0.000667	CcSEcCtD
Haloperidol—Vomiting—Dactinomycin—kidney cancer	8.58e-05	0.000664	CcSEcCtD
Haloperidol—Dyspnoea—Paclitaxel—kidney cancer	8.54e-05	0.000661	CcSEcCtD
Haloperidol—Somnolence—Paclitaxel—kidney cancer	8.51e-05	0.000659	CcSEcCtD
Haloperidol—Rash—Dactinomycin—kidney cancer	8.51e-05	0.000659	CcSEcCtD
Haloperidol—Nausea—Sunitinib—kidney cancer	8.47e-05	0.000655	CcSEcCtD
Haloperidol—Pancytopenia—Doxorubicin—kidney cancer	8.46e-05	0.000655	CcSEcCtD
Haloperidol—Dyspepsia—Paclitaxel—kidney cancer	8.43e-05	0.000652	CcSEcCtD
Haloperidol—Loperamide—ABCB1—kidney cancer	8.42e-05	0.106	CrCbGaD
Haloperidol—Neutropenia—Doxorubicin—kidney cancer	8.33e-05	0.000645	CcSEcCtD
Haloperidol—Decreased appetite—Paclitaxel—kidney cancer	8.32e-05	0.000644	CcSEcCtD
Haloperidol—Hypertension—Capecitabine—kidney cancer	8.31e-05	0.000643	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Paclitaxel—kidney cancer	8.27e-05	0.00064	CcSEcCtD
Haloperidol—Diarrhoea—Vincristine—kidney cancer	8.25e-05	0.000639	CcSEcCtD
Haloperidol—Constipation—Paclitaxel—kidney cancer	8.19e-05	0.000634	CcSEcCtD
Haloperidol—Anxiety—Capecitabine—kidney cancer	8.17e-05	0.000632	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	8.14e-05	0.00063	CcSEcCtD
Haloperidol—Photosensitivity reaction—Doxorubicin—kidney cancer	8.13e-05	0.000629	CcSEcCtD
Haloperidol—Weight increased—Doxorubicin—kidney cancer	8.11e-05	0.000627	CcSEcCtD
Haloperidol—Pruritus—Gemcitabine—kidney cancer	8.09e-05	0.000626	CcSEcCtD
Haloperidol—Weight decreased—Doxorubicin—kidney cancer	8.06e-05	0.000624	CcSEcCtD
Haloperidol—Hyperglycaemia—Doxorubicin—kidney cancer	8.03e-05	0.000622	CcSEcCtD
Haloperidol—Dry mouth—Capecitabine—kidney cancer	8.02e-05	0.000621	CcSEcCtD
Haloperidol—Nausea—Dactinomycin—kidney cancer	8.01e-05	0.00062	CcSEcCtD
Haloperidol—Dizziness—Vincristine—kidney cancer	7.97e-05	0.000617	CcSEcCtD
Haloperidol—Drowsiness—Doxorubicin—kidney cancer	7.94e-05	0.000615	CcSEcCtD
Haloperidol—Confusional state—Capecitabine—kidney cancer	7.92e-05	0.000613	CcSEcCtD
Haloperidol—Feeling abnormal—Paclitaxel—kidney cancer	7.89e-05	0.000611	CcSEcCtD
Haloperidol—Oedema—Capecitabine—kidney cancer	7.86e-05	0.000608	CcSEcCtD
Haloperidol—Diarrhoea—Gemcitabine—kidney cancer	7.82e-05	0.000606	CcSEcCtD
Haloperidol—Jaundice—Doxorubicin—kidney cancer	7.74e-05	0.000599	CcSEcCtD
Haloperidol—Nervous system disorder—Capecitabine—kidney cancer	7.71e-05	0.000597	CcSEcCtD
Haloperidol—Thrombocytopenia—Capecitabine—kidney cancer	7.69e-05	0.000596	CcSEcCtD
Haloperidol—Tachycardia—Capecitabine—kidney cancer	7.67e-05	0.000594	CcSEcCtD
Haloperidol—Vomiting—Vincristine—kidney cancer	7.66e-05	0.000593	CcSEcCtD
Haloperidol—Skin disorder—Capecitabine—kidney cancer	7.63e-05	0.000591	CcSEcCtD
Haloperidol—Urticaria—Paclitaxel—kidney cancer	7.61e-05	0.000589	CcSEcCtD
Haloperidol—Rash—Vincristine—kidney cancer	7.6e-05	0.000588	CcSEcCtD
Haloperidol—Hyperhidrosis—Capecitabine—kidney cancer	7.6e-05	0.000588	CcSEcCtD
Haloperidol—Dermatitis—Vincristine—kidney cancer	7.59e-05	0.000588	CcSEcCtD
Haloperidol—Body temperature increased—Paclitaxel—kidney cancer	7.57e-05	0.000586	CcSEcCtD
Haloperidol—Headache—Vincristine—kidney cancer	7.55e-05	0.000585	CcSEcCtD
Haloperidol—Hepatobiliary disease—Doxorubicin—kidney cancer	7.51e-05	0.000581	CcSEcCtD
Haloperidol—Anorexia—Capecitabine—kidney cancer	7.49e-05	0.00058	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—kidney cancer	7.41e-05	0.000574	CcSEcCtD
Haloperidol—Hypotension—Capecitabine—kidney cancer	7.34e-05	0.000568	CcSEcCtD
Haloperidol—Vomiting—Gemcitabine—kidney cancer	7.27e-05	0.000563	CcSEcCtD
Haloperidol—Rash—Gemcitabine—kidney cancer	7.21e-05	0.000558	CcSEcCtD
Haloperidol—Dermatitis—Gemcitabine—kidney cancer	7.2e-05	0.000558	CcSEcCtD
Haloperidol—Headache—Gemcitabine—kidney cancer	7.16e-05	0.000555	CcSEcCtD
Haloperidol—Nausea—Vincristine—kidney cancer	7.16e-05	0.000554	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—kidney cancer	7.13e-05	0.000552	CcSEcCtD
Haloperidol—Insomnia—Capecitabine—kidney cancer	7.11e-05	0.00055	CcSEcCtD
Haloperidol—Hypersensitivity—Paclitaxel—kidney cancer	7.05e-05	0.000546	CcSEcCtD
Haloperidol—Urinary tract disorder—Doxorubicin—kidney cancer	7.04e-05	0.000545	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—kidney cancer	7.01e-05	0.000542	CcSEcCtD
Haloperidol—Dyspnoea—Capecitabine—kidney cancer	7e-05	0.000542	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—kidney cancer	6.99e-05	0.000541	CcSEcCtD
Haloperidol—Dyspepsia—Capecitabine—kidney cancer	6.92e-05	0.000535	CcSEcCtD
Haloperidol—Visual impairment—Doxorubicin—kidney cancer	6.87e-05	0.000532	CcSEcCtD
Haloperidol—Decreased appetite—Capecitabine—kidney cancer	6.83e-05	0.000529	CcSEcCtD
Haloperidol—Nausea—Gemcitabine—kidney cancer	6.79e-05	0.000526	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Capecitabine—kidney cancer	6.78e-05	0.000525	CcSEcCtD
Haloperidol—Pruritus—Paclitaxel—kidney cancer	6.77e-05	0.000524	CcSEcCtD
Haloperidol—Constipation—Capecitabine—kidney cancer	6.72e-05	0.00052	CcSEcCtD
Haloperidol—Eye disorder—Doxorubicin—kidney cancer	6.66e-05	0.000516	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—kidney cancer	6.62e-05	0.000512	CcSEcCtD
Haloperidol—Diarrhoea—Paclitaxel—kidney cancer	6.55e-05	0.000507	CcSEcCtD
Haloperidol—Feeling abnormal—Capecitabine—kidney cancer	6.47e-05	0.000501	CcSEcCtD
Haloperidol—Angiopathy—Doxorubicin—kidney cancer	6.47e-05	0.000501	CcSEcCtD
Haloperidol—Immune system disorder—Doxorubicin—kidney cancer	6.44e-05	0.000498	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—kidney cancer	6.42e-05	0.000497	CcSEcCtD
Haloperidol—Dizziness—Paclitaxel—kidney cancer	6.33e-05	0.00049	CcSEcCtD
Haloperidol—Alopecia—Doxorubicin—kidney cancer	6.3e-05	0.000488	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—kidney cancer	6.25e-05	0.000483	CcSEcCtD
Haloperidol—Urticaria—Capecitabine—kidney cancer	6.24e-05	0.000483	CcSEcCtD
Haloperidol—Body temperature increased—Capecitabine—kidney cancer	6.21e-05	0.000481	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—kidney cancer	6.21e-05	0.00048	CcSEcCtD
Haloperidol—Vomiting—Paclitaxel—kidney cancer	6.09e-05	0.000471	CcSEcCtD
Haloperidol—Rash—Paclitaxel—kidney cancer	6.04e-05	0.000467	CcSEcCtD
Haloperidol—Dermatitis—Paclitaxel—kidney cancer	6.03e-05	0.000467	CcSEcCtD
Haloperidol—Headache—Paclitaxel—kidney cancer	6e-05	0.000464	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—kidney cancer	5.97e-05	0.000462	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—kidney cancer	5.85e-05	0.000453	CcSEcCtD
Haloperidol—Hypersensitivity—Capecitabine—kidney cancer	5.79e-05	0.000448	CcSEcCtD
Haloperidol—Anaemia—Doxorubicin—kidney cancer	5.74e-05	0.000444	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—kidney cancer	5.7e-05	0.000441	CcSEcCtD
Haloperidol—Nausea—Paclitaxel—kidney cancer	5.69e-05	0.00044	CcSEcCtD
Haloperidol—Vertigo—Doxorubicin—kidney cancer	5.58e-05	0.000432	CcSEcCtD
Haloperidol—Pruritus—Capecitabine—kidney cancer	5.56e-05	0.00043	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—kidney cancer	5.55e-05	0.00043	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—kidney cancer	5.38e-05	0.000416	CcSEcCtD
Haloperidol—Diarrhoea—Capecitabine—kidney cancer	5.38e-05	0.000416	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—kidney cancer	5.36e-05	0.000415	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—kidney cancer	5.27e-05	0.000408	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	5.25e-05	0.000406	CcSEcCtD
Haloperidol—Dizziness—Capecitabine—kidney cancer	5.2e-05	0.000402	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—kidney cancer	5.17e-05	0.0004	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—kidney cancer	5.11e-05	0.000395	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—kidney cancer	5.06e-05	0.000392	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—kidney cancer	5.06e-05	0.000392	CcSEcCtD
Haloperidol—Vomiting—Capecitabine—kidney cancer	5e-05	0.000387	CcSEcCtD
Haloperidol—Nervous system disorder—Doxorubicin—kidney cancer	4.97e-05	0.000385	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—kidney cancer	4.96e-05	0.000384	CcSEcCtD
Haloperidol—Rash—Capecitabine—kidney cancer	4.95e-05	0.000384	CcSEcCtD
Haloperidol—Dermatitis—Capecitabine—kidney cancer	4.95e-05	0.000383	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—kidney cancer	4.94e-05	0.000383	CcSEcCtD
Haloperidol—Headache—Capecitabine—kidney cancer	4.92e-05	0.000381	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—kidney cancer	4.92e-05	0.000381	CcSEcCtD
Haloperidol—Hyperhidrosis—Doxorubicin—kidney cancer	4.9e-05	0.000379	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—kidney cancer	4.83e-05	0.000374	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—kidney cancer	4.73e-05	0.000366	CcSEcCtD
Haloperidol—Nausea—Capecitabine—kidney cancer	4.67e-05	0.000361	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—kidney cancer	4.58e-05	0.000355	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—kidney cancer	4.52e-05	0.00035	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—kidney cancer	4.5e-05	0.000349	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—kidney cancer	4.46e-05	0.000345	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—kidney cancer	4.4e-05	0.000341	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—kidney cancer	4.37e-05	0.000339	CcSEcCtD
Haloperidol—Constipation—Doxorubicin—kidney cancer	4.33e-05	0.000335	CcSEcCtD
Haloperidol—Feeling abnormal—Doxorubicin—kidney cancer	4.17e-05	0.000323	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—kidney cancer	4.02e-05	0.000311	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—kidney cancer	4e-05	0.00031	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—kidney cancer	3.73e-05	0.000289	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—kidney cancer	3.58e-05	0.000277	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—kidney cancer	3.47e-05	0.000268	CcSEcCtD
Haloperidol—Dizziness—Doxorubicin—kidney cancer	3.35e-05	0.000259	CcSEcCtD
Haloperidol—Vomiting—Doxorubicin—kidney cancer	3.22e-05	0.000249	CcSEcCtD
Haloperidol—Rash—Doxorubicin—kidney cancer	3.19e-05	0.000247	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—kidney cancer	3.19e-05	0.000247	CcSEcCtD
Haloperidol—Headache—Doxorubicin—kidney cancer	3.17e-05	0.000246	CcSEcCtD
Haloperidol—Nausea—Doxorubicin—kidney cancer	3.01e-05	0.000233	CcSEcCtD
Haloperidol—HTR1D—Signaling Pathways—CDKN1B—kidney cancer	3.52e-06	6.18e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—RELA—kidney cancer	3.52e-06	6.17e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—ERBB2—kidney cancer	3.49e-06	6.14e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—BCHE—kidney cancer	3.49e-06	6.12e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KDR—kidney cancer	3.48e-06	6.11e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GSTP1—kidney cancer	3.47e-06	6.1e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MTOR—kidney cancer	3.45e-06	6.06e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—SLC5A5—kidney cancer	3.44e-06	6.05e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CDKN1B—kidney cancer	3.44e-06	6.05e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL2—kidney cancer	3.44e-06	6.05e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PTEN—kidney cancer	3.42e-06	6.01e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KDR—kidney cancer	3.42e-06	6.01e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KDR—kidney cancer	3.41e-06	6e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CDKN1B—kidney cancer	3.39e-06	5.95e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ITPR2—kidney cancer	3.39e-06	5.95e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ABCB1—kidney cancer	3.37e-06	5.92e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL2—kidney cancer	3.37e-06	5.92e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CCND1—kidney cancer	3.36e-06	5.89e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—PIK3CA—kidney cancer	3.35e-06	5.89e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—JUN—kidney cancer	3.35e-06	5.88e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—RAF1—kidney cancer	3.33e-06	5.85e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—SLC2A1—kidney cancer	3.33e-06	5.84e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CTNNB1—kidney cancer	3.32e-06	5.84e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL2—kidney cancer	3.32e-06	5.83e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—RELA—kidney cancer	3.31e-06	5.82e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—PIK3CA—kidney cancer	3.31e-06	5.81e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTGS2—kidney cancer	3.3e-06	5.8e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—ERBB2—kidney cancer	3.29e-06	5.79e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.29e-06	5.79e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CCND1—kidney cancer	3.29e-06	5.77e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—RAF1—kidney cancer	3.29e-06	5.77e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—JUN—kidney cancer	3.28e-06	5.76e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GSTP1—kidney cancer	3.27e-06	5.75e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GSTM1—kidney cancer	3.27e-06	5.75e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—RELA—kidney cancer	3.27e-06	5.75e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CTNNB1—kidney cancer	3.25e-06	5.72e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MTOR—kidney cancer	3.25e-06	5.71e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—ERBB2—kidney cancer	3.25e-06	5.71e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GSTP1—kidney cancer	3.25e-06	5.7e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PTEN—kidney cancer	3.24e-06	5.69e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CDKN1B—kidney cancer	3.23e-06	5.68e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CCND1—kidney cancer	3.23e-06	5.68e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.23e-06	5.67e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—JUN—kidney cancer	3.23e-06	5.67e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MTOR—kidney cancer	3.21e-06	5.63e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—APC—kidney cancer	3.2e-06	5.63e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KIT—kidney cancer	3.2e-06	5.63e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CTNNB1—kidney cancer	3.2e-06	5.62e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GSTM1—kidney cancer	3.19e-06	5.61e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PTEN—kidney cancer	3.17e-06	5.57e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL2—kidney cancer	3.17e-06	5.56e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KIT—kidney cancer	3.15e-06	5.54e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—APC—kidney cancer	3.15e-06	5.54e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—APC—kidney cancer	3.14e-06	5.52e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KIT—kidney cancer	3.14e-06	5.52e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PTEN—kidney cancer	3.12e-06	5.48e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.11e-06	5.47e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP1A1—kidney cancer	3.1e-06	5.45e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ABCB1—kidney cancer	3.1e-06	5.45e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ACHE—kidney cancer	3.09e-06	5.43e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTT1—kidney cancer	3.09e-06	5.43e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CCND1—kidney cancer	3.09e-06	5.42e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—JUN—kidney cancer	3.08e-06	5.41e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ABCB1—kidney cancer	3.07e-06	5.4e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—MAPK3—kidney cancer	3.07e-06	5.39e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CTNNB1—kidney cancer	3.06e-06	5.37e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CDKN1B—kidney cancer	3.05e-06	5.36e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—POMC—kidney cancer	3.05e-06	5.36e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP1A1—kidney cancer	3.03e-06	5.32e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—MAPK3—kidney cancer	3.02e-06	5.3e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—MAPK3—kidney cancer	3.01e-06	5.29e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—BRAF—kidney cancer	3.01e-06	5.29e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CDKN1B—kidney cancer	3.01e-06	5.29e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GSTM1—kidney cancer	3.01e-06	5.29e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—POMC—kidney cancer	3e-06	5.27e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—POMC—kidney cancer	2.99e-06	5.26e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—POMC—kidney cancer	2.99e-06	5.25e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL2—kidney cancer	2.99e-06	5.24e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GSTM1—kidney cancer	2.98e-06	5.24e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PTEN—kidney cancer	2.98e-06	5.23e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—BRAF—kidney cancer	2.96e-06	5.2e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—BRAF—kidney cancer	2.96e-06	5.19e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL2—kidney cancer	2.95e-06	5.17e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—VEGFA—kidney cancer	2.92e-06	5.14e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—SCARB1—kidney cancer	2.92e-06	5.14e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—MAPK1—kidney cancer	2.92e-06	5.13e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCND1—kidney cancer	2.91e-06	5.11e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—JUN—kidney cancer	2.9e-06	5.1e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS1—kidney cancer	2.89e-06	5.08e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CTNNB1—kidney cancer	2.88e-06	5.06e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTEN—kidney cancer	2.88e-06	5.06e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—MAPK1—kidney cancer	2.87e-06	5.05e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCND1—kidney cancer	2.87e-06	5.04e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—MAPK1—kidney cancer	2.87e-06	5.03e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—JUN—kidney cancer	2.87e-06	5.03e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—VEGFA—kidney cancer	2.86e-06	5.03e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP1A1—kidney cancer	2.85e-06	5.01e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CTNNB1—kidney cancer	2.84e-06	5e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PSMD7—kidney cancer	2.84e-06	4.99e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP1A1—kidney cancer	2.83e-06	4.97e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—POMC—kidney cancer	2.83e-06	4.96e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—VEGFA—kidney cancer	2.82e-06	4.95e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.81e-06	4.94e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PTEN—kidney cancer	2.81e-06	4.93e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—PIK3CA—kidney cancer	2.79e-06	4.9e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTP1—kidney cancer	2.77e-06	4.87e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PTEN—kidney cancer	2.77e-06	4.87e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MAPK3—kidney cancer	2.77e-06	4.86e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—KRAS—kidney cancer	2.76e-06	4.84e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	2.74e-06	4.82e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—PIK3CA—kidney cancer	2.74e-06	4.81e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—KRAS—kidney cancer	2.71e-06	4.77e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MAPK3—kidney cancer	2.71e-06	4.76e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—KRAS—kidney cancer	2.71e-06	4.75e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MYC—kidney cancer	2.69e-06	4.73e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—BCHE—kidney cancer	2.69e-06	4.73e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—VEGFA—kidney cancer	2.69e-06	4.73e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MAPK3—kidney cancer	2.67e-06	4.68e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.66e-06	4.67e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MYC—kidney cancer	2.64e-06	4.63e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MAPK1—kidney cancer	2.63e-06	4.62e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ABCB1—kidney cancer	2.63e-06	4.61e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MYC—kidney cancer	2.59e-06	4.56e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MAPK1—kidney cancer	2.58e-06	4.53e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.57e-06	4.51e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTM1—kidney cancer	2.55e-06	4.48e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.55e-06	4.48e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MAPK3—kidney cancer	2.55e-06	4.47e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—kidney cancer	2.54e-06	4.46e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MAPK1—kidney cancer	2.54e-06	4.46e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	2.53e-06	4.45e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—RAF1—kidney cancer	2.51e-06	4.42e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—kidney cancer	2.5e-06	4.4e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—RELA—kidney cancer	2.5e-06	4.4e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	2.49e-06	4.38e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ERBB2—kidney cancer	2.49e-06	4.37e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	2.49e-06	4.37e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KRAS—kidney cancer	2.49e-06	4.37e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MYC—kidney cancer	2.48e-06	4.35e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RAF1—kidney cancer	2.47e-06	4.35e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RAF1—kidney cancer	2.47e-06	4.34e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RELA—kidney cancer	2.46e-06	4.33e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RELA—kidney cancer	2.46e-06	4.32e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MTOR—kidney cancer	2.45e-06	4.31e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ERBB2—kidney cancer	2.45e-06	4.3e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ERBB2—kidney cancer	2.44e-06	4.29e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KRAS—kidney cancer	2.43e-06	4.28e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MAPK1—kidney cancer	2.42e-06	4.25e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP1A1—kidney cancer	2.42e-06	4.25e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MTOR—kidney cancer	2.41e-06	4.24e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PIK3CA—kidney cancer	2.41e-06	4.24e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MTOR—kidney cancer	2.41e-06	4.23e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MAPK3—kidney cancer	2.4e-06	4.22e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KRAS—kidney cancer	2.4e-06	4.21e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTGS2—kidney cancer	2.39e-06	4.19e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MAPK3—kidney cancer	2.37e-06	4.16e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MYC—kidney cancer	2.33e-06	4.1e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.32e-06	4.08e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—POMC—kidney cancer	2.31e-06	4.06e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1B—kidney cancer	2.3e-06	4.05e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MYC—kidney cancer	2.3e-06	4.05e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KRAS—kidney cancer	2.29e-06	4.02e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PIK3CA—kidney cancer	2.28e-06	4.01e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MAPK1—kidney cancer	2.28e-06	4.01e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	2.27e-06	3.98e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1B—kidney cancer	2.26e-06	3.97e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—POMC—kidney cancer	2.26e-06	3.97e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL2—kidney cancer	2.25e-06	3.96e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTGS2—kidney cancer	2.25e-06	3.96e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MAPK1—kidney cancer	2.25e-06	3.96e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PIK3CA—kidney cancer	2.24e-06	3.93e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL2—kidney cancer	2.22e-06	3.9e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL2—kidney cancer	2.21e-06	3.89e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—kidney cancer	2.21e-06	3.88e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PIK3CA—kidney cancer	2.2e-06	3.87e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCND1—kidney cancer	2.2e-06	3.86e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—JUN—kidney cancer	2.19e-06	3.85e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CTNNB1—kidney cancer	2.18e-06	3.82e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—kidney cancer	2.16e-06	3.8e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCND1—kidney cancer	2.16e-06	3.8e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—JUN—kidney cancer	2.16e-06	3.79e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCND1—kidney cancer	2.16e-06	3.79e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KRAS—kidney cancer	2.16e-06	3.79e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—JUN—kidney cancer	2.15e-06	3.78e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	2.14e-06	3.76e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTP1—kidney cancer	2.14e-06	3.76e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CTNNB1—kidney cancer	2.14e-06	3.75e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—kidney cancer	2.13e-06	3.74e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KRAS—kidney cancer	2.13e-06	3.74e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—POMC—kidney cancer	2.13e-06	3.74e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTEN—kidney cancer	2.12e-06	3.73e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—POMC—kidney cancer	2.11e-06	3.7e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PIK3CA—kidney cancer	2.1e-06	3.69e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTEN—kidney cancer	2.09e-06	3.67e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTEN—kidney cancer	2.08e-06	3.66e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTEN—kidney cancer	2.08e-06	3.66e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—kidney cancer	2.03e-06	3.57e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PIK3CA—kidney cancer	2.03e-06	3.57e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ABCB1—kidney cancer	2.03e-06	3.56e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.99e-06	3.49e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PIK3CA—kidney cancer	1.98e-06	3.48e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTM1—kidney cancer	1.97e-06	3.46e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTEN—kidney cancer	1.97e-06	3.45e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PIK3CA—kidney cancer	1.96e-06	3.43e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—kidney cancer	1.92e-06	3.37e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—kidney cancer	1.92e-06	3.37e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—kidney cancer	1.89e-06	3.32e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—kidney cancer	1.88e-06	3.31e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—kidney cancer	1.88e-06	3.3e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.87e-06	3.28e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTGS2—kidney cancer	1.84e-06	3.24e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MAPK3—kidney cancer	1.81e-06	3.18e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—POMC—kidney cancer	1.8e-06	3.17e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTGS2—kidney cancer	1.8e-06	3.16e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MAPK3—kidney cancer	1.78e-06	3.13e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MAPK3—kidney cancer	1.78e-06	3.13e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MYC—kidney cancer	1.76e-06	3.1e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MYC—kidney cancer	1.73e-06	3.05e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MYC—kidney cancer	1.73e-06	3.04e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MAPK1—kidney cancer	1.72e-06	3.03e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MAPK1—kidney cancer	1.7e-06	2.98e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS2—kidney cancer	1.7e-06	2.98e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MAPK1—kidney cancer	1.69e-06	2.97e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS2—kidney cancer	1.68e-06	2.95e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KRAS—kidney cancer	1.63e-06	2.86e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTEN—kidney cancer	1.61e-06	2.83e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KRAS—kidney cancer	1.6e-06	2.81e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KRAS—kidney cancer	1.6e-06	2.81e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTEN—kidney cancer	1.57e-06	2.76e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CA—kidney cancer	1.5e-06	2.63e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTEN—kidney cancer	1.48e-06	2.6e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	1.47e-06	2.59e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CA—kidney cancer	1.47e-06	2.58e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CA—kidney cancer	1.47e-06	2.58e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTEN—kidney cancer	1.47e-06	2.58e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—kidney cancer	1.45e-06	2.54e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS2—kidney cancer	1.44e-06	2.52e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—kidney cancer	1.42e-06	2.5e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—kidney cancer	1.42e-06	2.5e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—POMC—kidney cancer	1.39e-06	2.44e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CA—kidney cancer	1.39e-06	2.44e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTEN—kidney cancer	1.25e-06	2.2e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CA—kidney cancer	1.13e-06	1.99e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS2—kidney cancer	1.11e-06	1.95e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CA—kidney cancer	1.11e-06	1.95e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.04e-06	1.83e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.03e-06	1.82e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTEN—kidney cancer	9.67e-07	1.7e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CA—kidney cancer	8.84e-07	1.55e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CA—kidney cancer	6.82e-07	1.2e-05	CbGpPWpGaD
